Quantcast

Latest Sedatives Stories

2011-07-28 15:05:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2011. For the second quarter of 2011, the Company reported net income of $2.0 million, or $0.04 per share, compared to a net loss of $5.2 million, or $0.09 loss per share, for the same period in 2010. For the six months ended June 30, 2011, the Company reported net income of $4.9 million, or $0.09 per share, as compared to a net loss of...

2011-07-15 19:02:00

POINT RICHMOND, Calif., July 15, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S. Food and Drug Administration (FDA) that the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet), the company's lead product candidate, cannot be approved in its present form....

2011-07-14 22:42:00

POINT RICHMOND, Calif., July 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). In the Complete Response Letter, the FDA confirmed that Transcept has adequately demonstrated that Intermezzo® is efficacious for use...

2011-07-12 19:02:00

POINT RICHMOND, Calif., July 12, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet) on or before July 14, 2011, the PDUFA date assigned by the FDA for completion of the Intermezzo® NDA review. The FDA issues a...

2011-06-24 05:10:00

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less...

2011-06-17 13:21:26

UT Southwestern Medical Center scientists are shedding new light on why the anesthetic drug ketamine produces a fast-acting antidepressant response in patients with treatment-resistant depression. The drug's robust effect at low doses as a fast-acting antidepressant potentially has use in emergency rooms with high-risk patients. "Ketamine produces a very sharp increase that immediately relieves depression," said Dr. Lisa Monteggia, associate professor of psychiatry at UT Southwestern and...

2011-06-15 06:23:18

(Ivanhoe Newswire)--For people who suffer from insomnia, the metabolism in the brain's frontal cortex increases, making it difficult to fall asleep. According to a recent study, people with primary insomnia may be able to find relief by wearing a cap that cools the brain at night. One way to reduce cerebral metabolic activity is to use a process called "cerebral hypothermia," in which the frontal cerebral thermal transfers to cool the brain. But can this non-pharmaceutical method really cure...

2011-06-13 14:43:34

Study finds that treatment with frontal cerebral thermal transfer can eliminate insomnia symptoms People with primary insomnia may be able to find relief by wearing a cap that cools the brain during sleep, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS). According to the authors, a reduction in metabolism in the brain's frontal cortex occurs while...

2011-06-06 16:00:00

MORRISTOWN, N.J., June 6, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceuticals company, today announced that it has received final approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV. Distribution of the product has commenced. Actavis was the first company to launch Zolpidem Tartrate Extended-Release Tablets 6.25 mg strength in October 2010 with 180-day exclusivity. Zolpidem Tartrate...

2011-04-26 00:00:28

Following the death of her son, Julius, to the highly addictive bodybuilding/club drug GHB (gamma hydroxy butyrate), Suki deJong directed and produced the film All Apologies to increase awareness of GHB, commonly known as the "date-rape" drug. All Apologies, a short (22-min.) documentary, has been re-mastered and updated to spread the word about this insidious drug. (PRWEB) April 25, 2011 April 22, 2011 - Boynton Beach, Florida - Following the death of her son, Julius, to the highly...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related